Search Results - "Gæde, Peter"

Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria by Winther, Signe Abitz, Øllgaard, Jens Christian, Hansen, Tine Willum, von Scholten, Bernt Johan, Reinhard, Henrik, Ahluwalia, Tarunveer Singh, Wang, Zeneng, Gæde, Peter, Parving, Hans-Henrik, Hazen, Stanley, Pedersen, Oluf, Rossing, Peter

“…The trimethylamine N-oxide (TMAO) pathway is related to intestinal microbiota and has been associated to risk of cardiovascular disease (CVD). We investigated…”
Get full text

Home-based Intervention with Semaglutide Treatment of Neuroleptic-Related Prediabetes (HISTORI): protocol describing a prospective, randomised, placebo controlled and double-blinded multicentre trial by Ganeshalingam, Ashok Ainkaran, Uhrenholt, Nicolai Gundtoft, Arnfred, Sidse, Gæde, Peter Haulund, Bilenberg, Niels, Frystyk, Jan

“…IntroductionSubjects with schizophrenia have a 2–3 fold higher mortality rate than the general population and a reduced life expectancy of 10–20 years…”
Get full text

The independent association of myocardial extracellular volume and myocardial blood flow with cardiac diastolic function in patients with type 2 diabetes: a prospective cross-sectional cohort study by Bojer, Annemie S, Sørensen, Martin H, Madsen, Stine H, Broadbent, David A, Plein, Sven, Gæde, Peter, Madsen, Per L

“…Diffuse myocardial fibrosis and microvascular dysfunction are suggested to underlie cardiac dysfunction in patients with type 2 diabetes, but studies…”
Get full text

Reduced Myocardial Perfusion Reserve in Type 2 Diabetes Is Caused by Increased Perfusion at Rest and Decreased Maximal Perfusion During Stress by Sørensen, Martin H, Bojer, Annemie S, Pontoppidan, Julie R N, Broadbent, David A, Plein, Sven, Madsen, Per L, Gæde, Peter

“…To examine differences in myocardial blood flow (MBF) at rest and during stress between patients with type 2 diabetes and control subjects, and to identify…”
Get full text

Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes by Bojer, Annemie Stege, Sørensen, Martin Heyn, Vejlstrup, Niels, Goetze, Jens P, Gæde, Peter, Madsen, Per Lav

“…Cardiovascular magnetic resonance imaging (CMR) have described localised non-ischemic late gadolinium enhancement (LGE) lesions of prognostic importance in…”
Get full text

Myocardial Blood Flow Determination From Contrast‐Free Magnetic Resonance Imaging Quantification of Coronary Sinus Flow by Tingsgaard, Jakob Koefoed, Sørensen, Martin Heyn, Bojer, Annemie Stege, Anderson, Robert H., Broadbent, David Andrew, Plein, Sven, Gæde, Peter, Madsen, Per Lav

“…Background Determination of myocardial blood flow (MBF) with MRI is usually performed with dynamic contrast enhanced imaging (MBFDCE). MBF can also be…”
Get full text

Adverse effects with semaglutide: a protocol for a systematic review with meta-analysis and trial sequential analysis by Sillassen, Christina Dam Bjerregaard, Kamp, Caroline Barkholt, Petersen, Johanne Juul, Faltermeier, Pascal, Siddiqui, Faiza, Grand, Johannes, Dominguez, Helena, Frølich, Anne, Gæde, Peter Haulund, Gluud, Christian, Mathiesen, Ole, Jakobsen, Janus

“…IntroductionSemaglutide is increasingly used for the treatment of type 2 diabetes mellitus, overweight and other conditions. It is well known that semaglutide…”
Get full text

Expressions of mitochondria-related genes in pregnant women with subclinical hypothyroidism, and expressions of miRNAs in maternal and cord blood by Stryhn, Julie Kristine Guldberg, Larsen, Jacob, Pedersen, Palle Lyngsie, Gæde, Peter Haulund

“…Abstract Background Subclinical hypothyroidism in pregnancy and definition by upper thyrotropin (TSH) cutoff are controversial. As mitochondria are influenced…”
Get full text

Early signs of myocardial systolic dysfunction in patients with type 2 diabetes are strongly associated with myocardial microvascular dysfunction independent of myocardial fibrosis: a prospective cohort study by Bojer, Annemie S, Sørensen, Martin H, Madsen, Stine H, Broadbent, David A, Plein, Sven, Gæde, Peter, Madsen, Per L

“…Patients with diabetes demonstrate early left ventricular systolic dysfunction. Notably reduced global longitudinal strain (GLS) is related to poor outcomes,…”
Get full text

The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes by Jürgens, Mikkel, Schou, Morten, Hasbak, Philip, Kjær, Andreas, Wolsk, Emil, Zerahn, Bo, Brandt‐Jacobsen, Niels H., Gæde, Peter, Rossing, Peter, Faber, Jens, Inzucchi, Silvio E., Gustafsson, Finn, Kistorp, Caroline

“…Aims To investigate the effects of empagliflozin on measured glomerular filtration rate (mGFR), estimated plasma volume (PV) and estimated extracellular volume…”
Get full text

Fibroblast growth factor-23 is associated with imaging markers of diabetic cardiomyopathy and anti-diabetic therapeutics by Sørensen, Martin H, Bojer, Annemie S, Jørgensen, Niklas R, Broadbent, David A, Plein, Sven, Madsen, Per L, Gæde, Peter

“…The biomarker fibroblast growth factor-23 (FGF-23) has been associated with increased cardiovascular morbidity and mortality in both patients with and without…”
Get full text

A cost analysis of intensified vs conventional multifactorial therapy in individuals with type 2 diabetes: a post hoc analysis of the Steno-2 study by Gæde, Joachim, Oellgaard, Jens, Ibsen, Rikke, Gæde, Peter, Nørtoft, Emil, Parving, Hans-Henrik, Kjellberg, Jakob, Pedersen, Oluf

“…Aims/hypothesis Long-term follow-up of the Steno-2 study demonstrated that intensified multifactorial intervention increased median lifespan by 7.9 years and…”
Get full text

Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial by Jürgens, Mikkel, Schou, Morten, Hasbak, Philip, Kjær, Andreas, Wolsk, Emil, Zerahn, Bo, Wiberg, Mikkel, Brandt‐Jacobsen, Niels H., Gæde, Peter, Rossing, Peter, Faber, Jens, Inzucchi, Silvio E., Gustafsson, Finn, Kistorp, Caroline

“…Background Sodium–glucose cotransporter 2 inhibitors reduce hospitalizations for heart failure and cardiovascular death, although the underlying mechanisms…”
Get full text

Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes by Gæde, Peter, Vedel, Pernille, Larsen, Nicolai, Jensen, Gunnar V.H, Parving, Hans-Henrik, Pedersen, Oluf

“…Intensified, long-term intervention reduced cardiovascular and microvascular events by half. Patients with type 2 diabetes mellitus have a risk of death from…”
Get full text

Reduction of cardiac adipose tissue volume with short‐term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial by Brandt‐Jacobsen, Niels H., Jürgens, Mikkel, Hasbak, Philip, Gæde, Peter, Rossing, Peter, Rasmussen, Jon J., Andersen, Camillla Fuchs, Forman, Julie L., Faber, Jens, Inzucchi, Silvio E., Gustafsson, Finn, Schou, Morten, Kistorp, Caroline

“…Objective Ectopic accumulation of cardiac adipose tissue volume (CAT) has been associated with cardiac remodelling and cardiac dysfunction in type 2 diabetes…”
Get full text

Prevalence of urinary incontinence among women with diabetes in the Lolland‐Falster Health Study, Denmark by Løwenstein, Ea, Jepsen, Randi, Andersen, Lea L., Laigaard, Jennie, Møller, Lars A., Gæde, Peter, Bonde, Lisbeth, Gimbel, Helga

“…Aims To investigate the prevalence of urinary incontinence (UI) and UI subtypes (stress, urgency, and mixed UI) in women with or without diabetes mellitus; and…”
Get full text

Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis by Stougaard, Elisabeth B, Kristensen, Peter L, Kielgast, Urd, Andersen, Henrik U, Hamid, Yasmin, Gæde, Peter H, Søndergaard, Esben, Dørflinger, Gry H, Fjeldborg, Karen K, Hansen, Klavs W, Thomsen, Henrik H, Al-Imar, Thuraya M.J., Røder, Michael, Sridhar, Vikas S, Cherney, David, Rossing, Peter, Persson, Frederik

“…Background The indication for treatment of type 1 diabetes(T1D) with the sodium–glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn in…”
Get full text

Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes – a Danish nationwide observational study by Falkentoft, Alexander C., Andersen, Julie, Malik, Mariam Elmegaard, Selmer, Christian, Gæde, Peter Haulund, Staehr, Peter Bisgaard, Hlatky, Mark A., Fosbøl, Emil, Køber, Lars, Torp-Pedersen, Christian, Gislason, Gunnar H., Gerds, Thomas Alexander, Schou, Morten, Bruun, Niels E., Ruwald, Anne-Christine

“…Low socioeconomic position may affect initiation of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucacon-like-peptide-1 receptor agonists (GLP-1RA)…”
Get full text

Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial by Ersbøll, Mads, Jürgens, Mikkel, Hasbak, Philip, Kjær, Andreas, Wolsk, Emil, Zerahn, Bo, Brandt-Jacobsen, Niels H., Gæde, Peter, Rossing, Peter, Faber, Jens, Inzucchi, Silvio E., Gustafsson, Finn, Schou, Morten, Kistorp, Caroline

“…To investigate the effects of 13 weeks treatment with empagliflozin in patients with high-risk type-2 diabetes mellitus on echocardiographic measures of left…”
Get full text

A multidisciplinary, shared care clinic using personalized medicine and coordinated care in patients with concomitant type 2 diabetes and cardiovascular disease. Protocol and baseline characteristics by Pontoppidan, Julie Rye Noer, Nielsen, Emil Eik, Olsen, Michael Hecht, Skjødt, Michael Kriegbaum, Christensen, Jesper Olund, Raymond, Ilan Esra, Møller, Sara Hedlund, Soja, Anne Merete Boas, Gæde, Peter Haulund

“…Concomitant type 2 diabetes (T2DM) and cardiovascular disease (CVD) is frequent with a poor prognosis with high risk of comorbidities. Strict risk factor…”
Get full text